Neusignal Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Neusignal Therapeutics - overview
Established
2022
Location
Tokyo, Tokyo, Japan
Primary Industry
Biotechnology
About
Based in Tokyo, Japan, and founded in 2022, Neusignal Therapeutics Inc. engages in the research and development of drugs to treat dementia and mental disorders. In June 2026, Neusignal Therapeutics, Inc. raised JPY 5.
32 billion in series B funding from Fast Track Initiative, Keio Innovation Initiative, Mitsubishi UFJ Capital, FFG Venture Business Partners, SMBC Venture Capital and Nippon Venture Capital, with participation from Angel Bridge, DCI Partners Co. , Ltd. , Nissay Capital, Red Capital and THE GOGIN CAPITAL. The company is dedicated to advancing the treatment of central nervous system diseases, particularly Alzheimer's disease (AD), through the development of small-molecule drugs.
Neusignal Therapeutics also addresses the challenges posed by an aging population and the burden of nursing care, and protects brain health, through small-molecule oral drugs that enable fundamental treatment at home. The firm benefits from a strong collaboration system with Tohoku University and extensive networks with pharmaceutical companies and key opinion leaders in the AD field. The company will use the June 2026 funding to start a trial in the United States and hire personnel for future business partnerships.
Current Investors
Mitsubishi UFJ Capital, SMBC Venture Capital, Mizuho Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.neusignal-tx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Neusignal Therapeutics - financials
| Fiscal Year Ended | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|
| Revenue (USD) | - | - |
| % Revenue Growth (YoY) | - | - |
| EBITDA (USD) | - | - |
| Operating Income (USD) | - | - |
| Operating Margin | - | - |
| % EBITDA Margin | - | - |
| NET Income (USD) | - | - |
| % Net Margin | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.